CTLA4 and melanoma: A study showed that, under the background of anti-CTLA-4 immunotherapy, host-derived IDO can inhibit the infiltration and accumulation of tumor-reactive T cells in B16 melanoma tumors and weaken the anti-tumor efficacy.